Print version | PDF version | Send article | RSS feed

Singapore's first commercial developer of molecular diagnostic assays opens operations

03 Sep 2008 - Dx Assays Pte Ltd will commence operations on 8 September, as Singapore’s first commercial developer of molecular diagnostic assays, according to the compay. The company will develop and validate molecular diagnostic assays for biotech and pharmaceutical companies. This shall help Dx Assays’ clients in their drug discovery and development efforts, as well as assist in the tailored approach of personalized medicine.
 
Dx Assays is a joint venture between Qiagen and Bio*One Capital, the dedicated biomedical science investment company of EDB Investments.